Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...
This week's dividend activity included increased payouts from Taiwan Semiconductor Manufacturing Limited (TSM) and Goldman ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...
Pfizer Inc (Symbol: PFE) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $19.76B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a ...
Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4. Analysts expect the health care company to report quarterly earnings at 64 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback